Literature DB >> 20848468

Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort.

M J L Romberg-Camps1, Y Bol, P C Dagnelie, M A M Hesselink-van de Kruijs, A D M Kester, L G J B Engels, C van Deursen, W H A Hameeteman, M Pierik, F Wolters, M G V M Russel, R W Stockbrügger.   

Abstract

BACKGROUND: The importance of fatigue in chronic disease has been increasingly recognized; however, little is known about fatigue in inflammatory bowel disease (IBD). The aim of the present study was to investigate the prevalence and severity of fatigue and the impact on health-related quality of life (HRQoL) in patients included in a population-based IBD cohort in the Netherlands.
METHODS: IBD patients, diagnosed between January 1st, 1991, and January 1st, 2003, were followed up for a median of 7.1 years. They completed a questionnaire, which included a disease activity score, the Multidimensional Fatigue Inventory (MFI-20), the Inflammatory Bowel Disease Questionnaire (IBDQ), and the Short Form health survey (SF-36). Hemoglobin levels were recorded.
RESULTS: Data were available in 304 Crohn's disease (CD), 368 ulcerative colitis (UC), and 35 indeterminate colitis (IC) patients. During quiescent disease, the prevalence of fatigue was nearly 40%. MFI-20 and HRQoL scores were significantly worse in IBD patients having active disease. In a multivariate analysis, disease activity was positively related with the level of fatigue in both CD and UC. In UC, anemia influenced the general fatigue score independently of disease activity. Disease activity as well as fatigue were independently associated with an impaired IBDQ.
CONCLUSIONS: In IBD, even in remission, fatigue is an important feature. Both in CD and in UC, fatigue determined HRQoL independently of disease activity or anemia. This implies that in IBD patients physicians need to be aware of fatigue in order to better understand its impact and to improve the HRQoL.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20848468     DOI: 10.1002/ibd.21285

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  64 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 2.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

3.  Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.

Authors:  Mathurin Fumery; Siddharth Singh; Parambir S Dulai; Corinne Gower-Rousseau; Laurent Peyrin-Biroulet; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2017-06-16       Impact factor: 11.382

Review 4.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

5.  Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue.

Authors:  Lars-Petter Jelsness-Jørgensen; Svein-Oskar Frigstad; Bjørn Moum; Tore Grimstad; Randi Opheim; Jørgen Jahnsen; Tomm Bernklev
Journal:  United European Gastroenterol J       Date:  2016-10-06       Impact factor: 4.623

6.  Symptom clusters in adults with inflammatory bowel disease.

Authors:  Samantha Conley; Deborah D Proctor; Sangchoon Jeon; Robert S Sandler; Nancy S Redeker
Journal:  Res Nurs Health       Date:  2017-08-17       Impact factor: 2.228

7.  Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 Year.

Authors:  Ameer Abutaleb; Andrea Buchwald; Kenechukwu Chudy-Onwugaje; Patricia Langenberg; Miguel Regueiro; David A Schwartz; J Kathleen Tracy; Leyla Ghazi; Seema A Patil; Sandra M Quezada; Katharine M Russman; Charlene C Quinn; Guruprasad Jambaulikar; Dawn B Beaulieu; Sara Horst; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 8.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

9.  Self-reported Symptom Burden in Individuals with Inflammatory Bowel Disease.

Authors:  Dawn Farrell; Geraldine McCarthy; Eileen Savage
Journal:  J Crohns Colitis       Date:  2015-11-22       Impact factor: 9.071

Review 10.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.